Evidence map›Paper›PMID 40786984›Full record

ReviewCurrent pharmacology reports2025

Application of Physiologically-Based Pharmacokinetic (PBPK) Model in Drug Development and in Dietary Phytochemicals.

PoChung Chou, Ahmad Shannar, Yuxin Pan, Parv Dushyant Dave, Jiawei Xu, Ah-Ng Tony Kong

Abstract readReview
In one paragraph

Review in Current pharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Antibody-drug conjugate engineering: from design to efficacy and safety.Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

PoChung ChouGraduate Program in Pharmaceutical Science, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 USA.
Ahmad ShannarGraduate Program in Pharmaceutical Science, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 USA.
Yuxin PanGraduate Program in Pharmaceutical Science, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 USA.
Parv Dushyant DaveGraduate Program in Pharmaceutical Science, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 USA.
Jiawei XuGraduate Program in Pharmaceutical Science, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 USA.
Ah-Ng Tony KongDepartment of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854 USA.

Funding

Translational Research Support CoreP30ES005022 · NIEHS · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI BRIAN T BUCKLEY · 1988 to 2026
$47.4M
NIEHS NIH HHS P30 ES005022
6 · The paper itself

Abstract

Purpose of review: Physiologically-based pharmacokinetic (PBPK) modeling is a powerful tool to understand drug movements throughout the human body. Unlike classical PK methods that often lack sufficient physiological detail, PBPK integrates drug-specific properties with organism-specific physiological parameters to predict drug behavior in major body compartments, particularly site of action and providing high physiological realism. The aim of the review is to summarize application of PBPK modeling in drug development and in dietary phytochemicals. Recent findings: PBPK modeling is a versatile tool in drug development and phytochemical research. It predicts human PK from preclinical data, aiding lead optimization and candidate evaluation. The model mechanistically predicts drug-drug interactions (DDIs), supporting dose adjustments and reducing clinical trials. PBPK also enables formulation simulation for oral and modified-release drugs, optimizing bioavailability and predicting performance from in vitro data, thus reducing costly in vivo studies. Importantly, it extends drug knowledge to pediatric and special populations via virtual group simulations, enabling efficient, cost-effective dosage determination and less clinical trials. For dietary phytochemicals, PBPK modeling is well-suited for their complex mixture and variability. PBPK studies of phytochemicals demonstrate their utility for single components, mixtures, cross-species extrapolation, and complex metabolic processes, although challenges exist. Summary: PBPK modeling is a dynamic and quantitative tool offering comprehensive pharmacokinetic integration across various populations and regimens. Its importance is growing due to its application at diverse stages of drug development and its ability to adapt to complex substances, including natural products. Ultimately, PBPK modeling is significant for enhancing scientific rigor, expediting drug development and ensuring patient safety. Graphical Abstract:

Indexed as

Dietary phytochemicalsDrug-drug interactionsExtension to special populationFormulation simulationLead optimization and candidate evaluationPBPK

Identifiers

PMID40786984
PMCPMC12334468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.